RUA Life Sciences (GB:RUA) has released an update.
RUA Life Sciences PLC has reported a promising start to the financial year with revenues and orders surpassing management expectations, indicating likely half-year revenues of over £1.2 million, a significant increase from the previous year. The company has managed to control costs and expects a much-reduced loss compared to last year, while focusing on strategic growth through contract manufacturing and development in medical device sectors. RUA is also actively seeking partnerships and licensing opportunities for its vascular graft and heart valve leaflet technologies, with ongoing negotiations and developments expected to contribute to its targets.
For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.
